ASCO 2013

New data on breast cancer prognosis tests - EndoPredict and uPA/PAI-1 compared

(DGAP-Media / 07.06.2013 / 11:00)

Cologne/ Chicago - At the annual meeting of the «American Society of
Clinical Oncology» (ASCO) in Chicago, new data from clinical practice on
the breast cancer prognosis tests EndoPredict and uPA/PAI-1 were presented.
Both tests can be used for risk assessment in breast cancer. Here the goal
is to be able to provide a clear recommendation in favour of or against
chemotherapy. In a comparative study at the Technical University of Munich,
the influence on the final treatment decision was evaluated.

«Our prospective study shows for the first time that with the more modern
EndoPredict many more patients can be assigned to a low-risk group than
with the older uPA/PAI-1 test», explains Prof. Dr. Marion Kiechle, Director
of the Gynaecological Department of the Klinikum rechts der Isar, Technical
University of Munich. «In addition, EndoPredict is easier to use, since no
fresh tissue is needed, and it can be applied in a wider patient
population.»

Tumour samples from patients with hormone receptor-positive and
Her2/neu-negative breast cancer were examined. The gene-based EPclin score
was determined (37 % high risk, 63 % low risk), and when possible and
appropriate, the level of uPA/PAI-1 was de-termined, too (63 % high risk,
37 % low risk).

«The treatment decision was brought about mainly by the EPclin. Thanks to
the test re-sults, 44 percent of patients received no chemotherapy although
this had initially been planned. In 5 percent it was precisely reverse;
these patients received chemotherapy due to the increased risk identified
by the EPclin», explains Prof. Kiechle. «All in all, we can say that the
EndoPredict is the more versatile and powerful method for prognosis
determination. It is easier to use in clinical practice and allows to spare
another third of patients chemotherapy.»

EndoPredict is a multigenic prognosis test developed specifically for
breast cancer patients that has been clinically validated in three studies
involving over 2,200 patients and thus has an evidence level of I. In
patients with very good prognosis, chemotherapy can be foregone. As the
first test of its kind, EndoPredict is offered directly by the local
pathology as a medical service. The result can be available already after
one day, allowing timely planning of further treatment steps.
For further information please visit www.sividon.com or
www.endopredict.com.

Press Contact:
Sividon Diagnostics GmbH
Esther Linnenberg
Nattermannallee 1 | S19
D-50829 Köln (Cologne)
Phone: +49 / 221 / 669 561 70
Fax: +49 / 221 / 669 561 99
Email: [e-mail]


End of Media Release

---------------------------------------------------------------------

Issuer: Sividon Diagnostics GmbH
Key word(s): Health

07.06.2013 Dissemination of a Press Release, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


214791 07.06.2013